APYX Q2 2023: Advanced Energy Sales Surge 40% as Regulatory Tailwinds Drive U.S. Momentum

August 10, 2023 | By EarningsIQ Research

APYX posted a decisive rebound in advanced energy sales, up 40% year-over-year, as regulatory clarity and new product launches reinvigorated U.S. demand and set the stage for continued margin improvement. International softness and timing issues remain, but management’s confidence in the back half and reaffirmed guidance signal a reset in growth trajectory. Investors should watch execution on new indications and console upgrades for sustained outperformance.

Summary

• Regulatory Clearance Unlocks U.S. Growth: FDA updates and new 510(k) indications have reignited advanced energy adoption.
• Margin Expansion from Sales Mix Shift: Higher U.S. advanced energy contribution is driving gross margin gains.
• Pipeline and Portfolio Upgrades: Micro Handpiece and APEX One console launches are positioned to accelerate adoption into 2024.

Business Overview

APYX Medical develops and markets advanced energy surgical devices, with a core focus on Renuvion, a helium plasma and radiofrequency platform for soft tissue contraction used in cosmetic and surgical procedures. Revenue is generated through two main segments: Advanced Energy (sale of generators and disposable handpieces, primarily for aesthetic applications) and OEM (contract manufacturing of medical devices for third parties). In Q2, advanced energy accounted for the majority of revenue, with the U.S. market being the principal driver.

Performance Analysis

APYX delivered total revenue growth of 32% year-over-year, propelled by a 40% surge in advanced energy sales, which now dominate the company’s revenue mix. The U.S. advanced energy business was the standout, growing 38% year-over-year, as the FDA’s updated safety communication and new clinical indications unlocked pent-up demand, particularly for the new APEX One console. International generator sales also grew, offsetting handpiece order timing issues in certain OUS (Outside U.S.) markets.

Gross margin improved to 68.4%, up from 67.2% a year ago, reflecting a higher mix of advanced energy sales, especially in the U.S., and favorable product and geographic mix. Operating expenses were tightly managed, rising just 2.5% year-over-year, with notable reductions in professional services costs and a focus on SG&A discipline. The company’s operating loss narrowed significantly, aided by a $2.7 million gain from a property sale-leaseback and improved underlying operating leverage. Cash flow from operations improved, and the balance sheet was bolstered by an $8.1 million IRS tax refund and the sale-leaseback proceeds.

• U.S. Advanced Energy Outpaces Expectations: Generator sales to new and existing customers, boosted by the APEX One console, drove the bulk of growth.
• International Sales Mixed by Geography: Latin America and Asia-Pacific saw strong generator demand, while Europe and Middle East lagged due to order timing.
• OEM Segment Remains Stable: OEM sales, though down 4% YoY, exceeded internal expectations, providing a buffer to overall results.

Despite international handpiece softness, management reaffirmed full-year and Q3 guidance, banking on back-half order recovery and continued U.S. momentum. The improving gross margin and reduced cash burn are key signals of operational discipline as APYX pivots toward profitability.

Executive Commentary

Strategic Positioning

1. Regulatory Tailwinds and Indication Expansion

APYX secured multiple 510(k) clearances, most notably for the Renuvion APR handpiece post-liposuction, directly addressing prior FDA safety concerns. The May 2023 FDA update removed key barriers, enabling broader clinical adoption and fueling U.S. generator sales. This regulatory momentum is foundational for both near-term growth and long-term market share gains.

2. Product Portfolio Innovation and Upgrade Cycle

The APEX One console, next-generation generator platform, is driving both replacement and new customer demand, aided by a trade-in upgrade program. The limited market release of the Renuvion Micro Handpiece targets new anatomical applications (face, hands, knees), expanding the addressable market and reinforcing the value of system upgrades. These launches are designed to accelerate the installed base and recurring handpiece revenue into 2024.

3. Margin Expansion via U.S. Mix and Cost Discipline

With U.S. advanced energy sales rising as a share of total revenue, APYX is enjoying higher gross margins, as U.S. sales are structurally more profitable. Operating expense growth has been contained, with targeted investment in sales force education and direct-to-consumer awareness, while leveraging recent capital inflows to support growth initiatives without compromising the path to profitability.

4. International Growth Recovery and Market Expansion

International generator sales showed strength in select regions, but handpiece order timing muted OUS results. Management expects a rebound in international handpiece orders in the second half, and continues to pursue new registrations in large untapped markets such as South Korea and China, though current guidance excludes contributions from these geographies.

5. Leveraging Macro Trends in Aesthetics

APYX is positioning Renuvion as the preferred technology for skin contraction, capitalizing on tailwinds from weight loss drug adoption (e.g., Ozempic), which is expected to drive demand for skin tightening procedures. Direct-to-consumer marketing and clinical evidence generation are intended to support this trend and differentiate Renuvion in a competitive landscape.

Key Considerations

APYX’s Q2 marked a strategic inflection, with regulatory clarity and product launches re-energizing growth, but execution risks remain as the company scales new indications and international markets.

Key Considerations:

• U.S. Demand Catalysts: Recent FDA clearance and safety communication update are driving rapid generator adoption and supporting handpiece pull-through.
• International Timing and Mix: OUS handpiece order delays are expected to reverse in H2, but execution will be critical to meeting guidance.
• Portfolio Leverage: The Micro Handpiece launch, requiring APEX One upgrades, could drive incremental console sales and expand procedure types.
• Margin and Cash Trajectory: Favorable sales mix and cost discipline are improving gross margin and narrowing losses, with cash position strengthened by tax refund and asset monetization.
• Regulatory and Competitive Dynamics: Enforcement of on-label claims remains uneven, potentially impacting competitive positioning and market adoption rates.

Risks

International handpiece order timing remains a near-term risk, with guidance dependent on back-half recovery that has yet to materialize. Regulatory enforcement on competitors is lagging, which could blunt APYX’s differentiation from new indications. Macro headwinds, such as procedure volumes and consumer demand for aesthetics, could also introduce volatility, particularly if U.S. momentum stalls or international approvals are delayed.

Forward Outlook

For Q3 2023, APYX guided to:

• Total revenue of $15 to $16 million
• Advanced energy sales growth of 65% to 76% YoY, OEM sales down approximately 7% YoY

For full-year 2023, management reaffirmed guidance:

• Total revenue of $59 to $62 million, advanced energy revenue of $51 to $54 million, OEM revenue of approximately $8 million
• Gross margin of 66.5% to 67.5%, net loss of approximately $10.5 million

Management highlighted several factors that frame their outlook:

• Continued U.S. generator and handpiece adoption following regulatory updates
• Expected recovery of international handpiece orders in the second half
• Full commercial launch of the Micro Handpiece in Q4 and ongoing direct-to-consumer initiatives

Takeaways

APYX’s Q2 performance marks a return to growth, led by regulatory-driven U.S. momentum and a disciplined operating model. The success of new product launches and international order recovery will define the path to profitability and sustained margin expansion.

• Regulatory Resolution as Growth Catalyst: FDA clearances and updated safety communication are directly translating into higher generator sales and renewed customer confidence.
• Margin Resilience from U.S. Mix: Rising U.S. advanced energy sales are structurally accretive to gross margin and operating leverage, supporting cash burn reduction.
• Execution Watchpoints for H2: Investors should monitor the pace of Micro Handpiece adoption, conversion to APEX One consoles, and the timing of international handpiece orders for evidence of sustained momentum.

Conclusion

APYX’s Q2 results demonstrate a clear inflection in advanced energy growth, margin improvement, and regulatory positioning. Sustained execution on new product launches and international recovery will be central to extending this momentum into 2024 and beyond.

Industry Read-Through

The APYX quarter underscores the importance of regulatory clarity as a catalyst for adoption in the energy-based aesthetics sector. Competitors lacking specific FDA indications may face increased scrutiny and commercial friction, especially as APYX leverages its differentiated label and direct-to-consumer marketing. The impact of weight loss drugs on demand for skin tightening procedures is an emerging tailwind for the entire aesthetics industry, while the trend toward platform upgrades and procedure diversification will favor companies with robust R&D and clinical evidence pipelines. International market access and regulatory harmonization remain gating factors for global expansion in medical aesthetics.

APYX Healthcare Medical Devices Aesthetics Regulatory Advanced Energy Margin Expansion Product Launch